NNC0487-0111 for Obesity and Type 2 Diabetes

(AMAZE 2 Trial)

This trial explores whether a new treatment, NNC0487-0111 (an experimental treatment), can safely and effectively aid individuals with obesity and type 2 diabetes. Participants will receive either the treatment or a placebo, a substance with no active medicine, through weekly injections. The study evaluates the treatment's effectiveness alongside a healthy diet and increased physical activity. Individuals who have had type 2 diabetes for at least six months and manage it with lifestyle changes or up to three oral medications may be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications. However, it mentions that if you are on oral antidiabetic drugs, your treatment should be stable before screening.

An earlier study found NNC0487-0111 to be safe for humans. Research shows it is generally well-tolerated, with most people experiencing only mild side effects, such as nausea or mild stomach issues, which are common when starting new treatments. Importantly, that study observed significant weight loss and improved blood sugar levels, suggesting the treatment works effectively with manageable safety. Since this trial is in a later phase, earlier tests demonstrated positive safety results, allowing the research to progress.¹²³⁴⁵

Researchers are excited about NNC0487-0111 for treating obesity and type 2 diabetes because it offers a potentially new approach compared to current options like GLP-1 receptor agonists and SGLT-2 inhibitors. This treatment is administered subcutaneously once a week, which could mean fewer doses and better patient compliance. Unlike standard treatments, which primarily focus on enhancing insulin action or promoting glucose excretion, NNC0487-0111 might have a unique mechanism that targets weight loss directly, complementing lifestyle changes like diet and exercise. Such features could make it a promising addition to the management of obesity and type 2 diabetes.

Research has shown that NNC0487-0111 could help treat obesity and type 2 diabetes. Studies have found that it significantly lowers both body weight and HbA1c levels, a measure of blood sugar control. The effects depend on the dose, with higher doses typically leading to better results. Early trials suggested it also reduces food intake and appetite, aiding in weight loss. In this trial, participants will receive different dose levels of NNC0487-0111 or a placebo, offering a promising option for those dealing with these conditions.¹²³⁶⁷